Anne C Moore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8931580/publications.pdf

Version: 2024-02-01

126858 161767 3,364 55 33 54 citations h-index g-index papers 61 61 61 4120 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The success of microneedle-mediated vaccine delivery into skin. Human Vaccines and Immunotherapeutics, 2016, 12, 2975-2983.	1.4	370
2	Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 14017-14022.	3.3	236
3	Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine, 1995, 13, 1741-1749.	1.7	149
4	Effective induction of high-titer antibodies by viral vector vaccines. Nature Medicine, 2008, 14, 819-821.	15.2	148
5	Coated microneedle arrays for transcutaneous delivery of live virus vaccines. Journal of Controlled Release, 2012, 159, 34-42.	4.8	141
6	Effects of Antigen and Genetic Adjuvants on Immune Responses to Human Immunodeficiency Virus DNA Vaccines in Mice. Journal of Virology, 2002, 76, 243-250.	1.5	115
7	Progress in DNA-based heterologous prime-boost immunization strategies for malaria. Immunological Reviews, 2004, 199, 126-143.	2.8	115
8	Determination of parameters for successful spray coating of silicon microneedle arrays. International Journal of Pharmaceutics, 2011, 415, 140-149.	2.6	114
9	Production of dissolvable microneedles using an atomised spray process: Effect of microneedle composition on skin penetration. European Journal of Pharmaceutics and Biopharmaceutics, 2014, 86, 200-211.	2.0	111
10	The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine, 1999, 17, 2517-2527.	1.7	105
11	Singleâ€dose immunogenicity and protective efficacy of simian adenoviral vectors against <i>Plasmodium berghei</i> . European Journal of Immunology, 2008, 38, 732-741.	1.6	95
12	Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance. Journal of Immunology, 2005, 175, 7264-7273.	0.4	89
13	Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods. Journal of Controlled Release, 2016, 225, 192-204.	4.8	86
14	Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cellular and Molecular Life Sciences, 2012, 69, 389-404.	2.4	84
15	The immune system and stroke: from current targets to future therapy. Immunology and Cell Biology, 2019, 97, 5-16.	1.0	78
16	Microneedle Array Design Determines the Induction of Protective Memory CD8+ T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice. PLoS ONE, 2011, 6, e22442.	1.1	68
17	Single-Dose Protection against <i>Plasmodium berghei</i> by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A. Journal of Virology, 2008, 82, 3822-3833.	1.5	67
18	Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1. Scientific Reports, 2013, 3, 1443.	1.6	67

#	Article	IF	CITATIONS
19	Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine, 2006, 24, 3026-3034.	1.7	65
20	Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1 Induce Antibody- and T Cell-Mediated Multistage Protection against Malaria. Cell Host and Microbe, 2009, 5, 95-105.	5.1	65
21	Safety, Immunogenicity, and Efficacy of Prime-Boost Immunization with Recombinant Poxvirus FP9 and Modified Vaccinia Virus Ankara Encoding the Full-Length Plasmodium falciparum Circumsporozoite Protein. Infection and Immunity, 2006, 74, 2706-2716.	1.0	62
22	Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity. Journal of Immunology, 2005, 175, 599-606.	0.4	60
23	A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 290-295.	3.3	59
24	Dissolvable microneedle fabrication using piezoelectric dispensing technology. International Journal of Pharmaceutics, 2016, 500, 1-10.	2.6	55
25	Soluble IL- $2R\hat{l}\pm$ (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice. PLoS ONE, 2012, 7, e47748.	1.1	55
26	Microneedle-mediated immunization of an adenovirus-based malaria vaccine enhances antigen-specific antibody immunity and reduces anti-vector responses compared to the intradermal route. Scientific Reports, 2014, 4, 6154.	1.6	46
27	Immunomodulatory Therapeutic Strategies in Stroke. Frontiers in Pharmacology, 2019, 10, 630.	1.6	45
28	Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge. Infection and Immunity, 2007, 75, 5819-5826.	1.0	43
29	Microneedle technology for immunisation: Perception, acceptability and suitability for paediatric use. Vaccine, 2016, 34, 723-734.	1.7	40
30	Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles. Journal of Pharmacy and Pharmacology, 2013, 65, 1451-1462.	1,2	39
31	Trends in drug- and vaccine-based dissolvable microneedle materials and methods of fabrication. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 173, 54-72.	2.0	38
32	The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment. Scientific Reports, 2013, 3, 1706.	1.6	36
33	Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles. International Journal of Pharmaceutics, 2014, 472, 206-213.	2.6	36
34	Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies. Journal of Controlled Release, 2019, 311-312, 96-103.	4.8	35
35	Views of parents regarding human papillomavirus vaccination: A systematic review and meta-ethnographic synthesis of qualitative literature. Research in Social and Administrative Pharmacy, 2019, 15, 331-337.	1.5	32
36	Induction of CD8+ T cell responses and protective efficacy following microneedle-mediated delivery of a live adenovirus-vectored malaria vaccine. Vaccine, 2015, 33, 3248-3255.	1.7	30

#	Article	IF	CITATIONS
37	Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs. Journal of Controlled Release, 2019, 308, 14-28.	4.8	29
38	A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. International Journal of Pharmaceutics, 2020, 586, 119390.	2.6	29
39	Approaches To New Vaccines. Critical Reviews in Biotechnology, 1998, 18, 257-282.	5.1	23
40	Toll-like receptor agonists as adjuvants for inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine. Veterinary Immunology and Immunopathology, 2019, 212, 27-37.	0.5	19
41	Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction. Vaccine, 2004, 22, 4326-4331.	1.7	18
42	Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity. Expert Review of Vaccines, $2007, 6, 111-121$.	2.0	18
43	Acceptability of microneedle-patch vaccines: A qualitative analysis of the opinions of parents. Vaccine, 2017, 35, 4896-4904.	1.7	18
44	Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells. Cellular Immunology, 2004, 228, 15-19.	1.4	17
45	Orally administered adenoviral-based vaccine induces respiratory mucosal memory and protection against RSV infection in cotton rats. Vaccine, 2018, 36, 4265-4277.	1.7	17
46	Parent Attitudes about Childhood Vaccines: Point Prevalence Survey of Vaccine Hesitancy in an Irish Population. Pharmacy (Basel, Switzerland), 2021, 9, 188.	0.6	13
47	The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia. Journal of Neuroinflammation, 2021, 18, 37.	3.1	12
48	A systematic approach to map the adolescent human papillomavirus vaccine decision and identify intervention strategies to address vaccine hesitancy. Public Health, 2019, 177, 71-79.	1.4	11
49	Low Adenovirus Vaccine Doses Administered to Skin Using Microneedle Patches Induce Better Functional Antibody Immunogenicity as Compared to Systemic Injection. Vaccines, 2021, 9, 299.	2.1	10
50	Immune responses induced by inactivated porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in neonatal pigs using different adjuvants. Veterinary Immunology and Immunopathology, 2021, 232, 110170.	0.5	8
51	Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities. Frontiers in Pharmacology, 0, 13, .	1.6	6
52	A Video-Based Behavioral Intervention Associated with Improved HPV Knowledge and Intention to Vaccinate. Vaccines, 2022, 10, 562.	2.1	5
53	Early immune responses in skin and lymph node after skin delivery of Toll-like receptor agonists in neonatal and adult pigs. Vaccine, 2021, 39, 1857-1869.	1.7	4
54	Histological, behavioural and flow cytometric datasets relating to acute ischaemic stroke in young, aged and ApoE \hat{a} '/ \hat{a} ' mice in the presence and absence of immunomodulation with fingolimod. Data in Brief, 2021, 36, 107146.	0.5	3

#	Article	IF	CITATIONS
55	Melanoma-conditioned medium promotes cytotoxic immune responses by murine bone marrow-derived monocytes despite their expression of '2' markers. Cancer Immunology, Immunotherapy, 2019, 68, 1455-1465.	2.0	2